Immunome Expands Team with Stock Options to Enhance Cancer Therapy Development

Immunome Expands Workforce with Strategic Inducement Awards to Support Cancer Therapy Development

Immunome, Inc., a biotechnology firm based in Bothell, Washington, continues to bolster its commitment to developing innovative cancer therapies by enhancing its workforce. On January 2, 2025, the company announces the granting of inducement awards consisting of non-statutory stock options totaling 45,000 shares to four new employees under its 2024 Inducement Plan. This strategic move, which aligns with Nasdaq Listing Rule 5635(c)(4), underscores Immunome’s efforts to attract top talent essential for advancing its pioneering cancer treatment initiatives.

The stock options come with an exercise price of $10.53 per share, reflective of the company's closing price on the grant date. Immunome structures the vesting schedule to incentivize long-term commitment, with 25% of the options vesting after one year and the remaining shares vesting monthly over the subsequent three years, contingent upon the employees' ongoing service. This approach not only rewards the new hires but also aligns their interests with the company’s mission to enhance patient outcomes through targeted therapies.

Immunome’s current pipeline includes promising candidates aimed at treating various types of cancer. Among these is AL102, a gamma secretase inhibitor that is undergoing a Phase 3 trial for desmoid tumors. Furthermore, the company is on track to file investigational new drug applications (INDs) for two additional antibody-drug conjugates—IM-1021 and IM-3050—expected by the first quarter of 2025. The leadership team at Immunome brings a wealth of experience in developing advanced targeted cancer therapies, including antibody-drug conjugates, positioning the company for potential breakthroughs in cancer treatment.

In addition to its workforce expansion, Immunome emphasizes the importance of its forward-looking statements regarding pipeline progress and regulatory timelines. The company acknowledges that these projections are subject to various risks and uncertainties that may affect actual results. By continuously refining its focus on innovative cancer therapies, Immunome aims to make significant strides in improving treatment outcomes for patients battling cancer.

As Immunome moves forward, its commitment to advancing targeted therapies remains unwavering, with a keen eye on both talent acquisition and pipeline development. The strategic inducement awards reflect the company's proactive approach to fostering a dedicated team capable of driving its mission to deliver first-in-class cancer treatments. For further details about Immunome's initiatives and pipeline, interested parties can visit their website at www.immunome.com.